Angiotensin converting enzyme inhibitors for prevention of new-onset type 2 diabetes mellitus: A meta-analysis of 72,128 patients

International Journal of Cardiology

Volumn 167, Issue 6, 2013, Pages 2605-2610

  Geng, Deng Feng ^a   Jin, Dong Mei ^a   Wu, Wei ^a   Liang, Yong De ^a   Wang, Jing Feng ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Angiotensin converting enzyme inhibitors; Diabetes type 2; Hypertension; Impaired fasting glucose; Impaired glucose tolerance

Indexed keywords

AMLODIPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FELODIPINE; GLUCOSE; HYDROCHLOROTHIAZIDE; ISRADIPINE; LISINOPRIL; METOPROLOL; PERINDOPRIL; PLACEBO; RAMIPRIL; TRANDOLAPRIL;

ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; COMORBIDITY; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFECT; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RISK REDUCTION; SYSTEMATIC REVIEW;

ANGIOTENSIN CONVERTING ENZYME INHIBITORS; DIABETES TYPE 2; HYPERTENSION; IMPAIRED FASTING GLUCOSE; IMPAIRED GLUCOSE TOLERANCE;

AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE INTOLERANCE; HUMANS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84883774692     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2012.06.125     Document Type: Article

References (25)

1. M.I. Harris Diabetes in America: epidemiology and scope of the problem Diabetes Care 21 1998 C11 C14
2. C.C. Cowie, K.F. Rust, and E.S. Ford Full accounting of diabetes and pre-diabetes in the U.S. population in 1988-1994 and 2005-2006 Diabetes Care 32 2009 287 294
3. T.W. Gress, F.J. Nieto, E. Shahar, M.R. Wofford, and F.L. Brancati Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis risk in communities study N Engl J Med 342 2000 905 912
4. A.J. Scheen Renin-angiotensin system inhibition prevents type 2 diabetes mellitus: part 1: a meta-analysis of randomised clinical trials Diabetes Metab 30 2004 487 496
5. H. Abuissa, P.G. Jones, S.P. Marso, and J.H. O'Keefe Angiotensin- converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials J Am Coll Cardiol 46 2005 821 826
6. E.L. Gillespie, C.M. White, M. Kardas, M. Lindberg, and C.I. Coleman The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes Diabetes Care 28 2005 2261 2266
7. K.A. Jandeleit-Dahm, C. Tikellis, C.M. Reid, C.I. Johnston, and M.E. Cooper Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes J Hypertens 23 2005 463 473
8. DREAM Trial Investigators, J. Bosch, and S. Yusuf Effect of ramipril on the incidence of diabetes N Engl J Med 355 15 2006 1551 1562
9. K.M. Fox European trial on reduction of cardiac events with perindopril in stable coronary artery disease investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study) Lancet 362 9386 2003 782 788
10. The Cochrane Collaboration Cochrane handbook for systematic reviews of interventions 4.2.5. May 2005
11. S. Yusuf, H. Gerstein, and B. Hoogwerf Ramipril and the development of diabetes JAMA 286 15 2001 1882 1885
12. E. Braunwald, M.J. Domanski, and S.E. Fowler Angiotensin-converting- enzyme inhibition in stable coronary artery disease N Engl J Med 351 20 2004 2058 2068
13. E. Vermes, A. Ducharme, M.G. Bourassa, M. Lessard, M. White, and J.C. Tardif Studies of left ventricular dysfunction. Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the studies of left ventricular dysfunction (SOLVD) Circulation 107 9 2003 1291 1296
14. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group The antihypertensive and lipid-lowering treatment to prevent heart attack trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT) JAMA 288 23 2002 2981 2997
15. L.M. Wing, C.M. Reid, and P. Ryan A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly N Engl J Med 348 7 2003 583 592
16. L. Hansson, L.H. Lindholm, and L. Niskanen Effect of angiotensin- converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the captopril prevention project (CAPPP) randomised trial Lancet 353 9153 1999 611 616
17. L. Hansson, L.H. Lindholm, and T. Ekbom Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish trial in old patients with hypertension-2 study Lancet 354 9192 1999 1751 1756
18. G.R. Dagenais, J. Pogue, K. Fox, M.L. Simoons, and S. Yusuf Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials Lancet 368 9535 2006 581 588
19. C.A. Daly, P. Hildebrandt, and M. Bertrand Adverse prognosis associated with the metabolic syndrome in established coronary artery disease: data from the EUROPA trial Heart 93 11 2007 1406 1411
20. NAVIGATOR Study Group, J.J. McMurray, R.R. Holman, S.M. Haffner, M.A. Bethel, and B. Holzhauer Effect of valsartan on the incidence of diabetes and cardiovascular events N Engl J Med 362 2010 1477 1490
21. E.L. Kuti, W.L. Baker, and C.M. White The development of new-onset type 2 diabetes associated with choosing a calcium channel blocker compared to a diuretic or beta-blocker Curr Med Res Opin 23 2007 1239 1244
22. S. Bangalore, S. Parkar, E. Grossman, and F.H. Messerli A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus Am J Cardiol 100 8 2007 1254 1262
23. J.A. Staessen, J.G. Wang, and L. Thijs Cardiovascular prevention and blood pressure reduction: a meta-analysis Lancet 358 2001 1305 1315
24. Blood Pressure Lowering Treatment Trialists' Collaboration Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials Lancet 362 2003 1527 1535
25. J.G. Wang, Y. Li, S.S. Franklin, and M. Safar Prevention of stroke and myocardial infarction by amlodipine and angiotensin receptor blockers: a quantitative overview Hypertension 50 2007 181 188